Models of hematopoietic malignancies: chronic myeloid leukemia

Drug Discovery Today: Disease Models

Volumn 3, Issue 2, 2006, Pages 183-189

  Cuiffo, Benjamin ^a   Ren, Ruibao ^a  

^a BRANDEIS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; BCR ABL PROTEIN; FLUOROURACIL; GAG PROTEIN; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR; RETROVIRUS VECTOR;

CANCER MODEL; CARCINOGENESIS; CELL RENEWAL; CHRONIC MYELOID LEUKEMIA; DRUG EFFICACY; DRUG RESEARCH; DRUG TARGETING; GENETIC TRANSDUCTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL LINE; MALIGNANT TRANSFORMATION; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; TRANSGENIC MOUSE;

EID: 33747378628     PISSN: 17406757     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmod.2006.05.009     Document Type: Review

References (54)

1. Ghaffari S., et al. Growth factor independence and BCR-ABL transformation: promise and pitfalls of murine model systems and assays. Leukemia 13 (1999) 1200-1206
2. Nowell P.C., and Hungerford D.A. A minute chromosome in human chronic granulocytic leukemia. Science 132 (1960) 1497
3. Rowly J.D. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243 (1973) 290-293
4. Shtivelman E., et al. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 315 (1985) 550-554
5. Walker L.C., et al. Novel chimaeric protein expressed in Philadelphia positive acute lymphoblastic leukaemia. Nature 329 (1987) 851-853
6. Wong S., and Witte O.N. The BCR-ABL story: bench to bedside and back. Annu. Rev. Immunol. 22 (2004) 247-306
7. Fialkow P.J., et al. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am. J. Med. 63 (1977) 125-130
8. Fialkow P.J., et al. Clonal origin of chronic myelocytic leukemia in man. Proc. Natl. Acad. Sci. U S A 58 (1967) 1468-1471
9. Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat. Rev. Cancer 5 (2005) 172-183
10. Fiskus W., et al. Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against BCR-ABL expressing human leukemia cells. Blood 108 2 (2006) 645-652
11. Deininger M.W., et al. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 90 (1997) 3691-3698
12. Druker B.J., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of BCR-ABL positive cells. Nat. Med. 2 (1996) 561-566
13. Lozzio C.B., and Lozzio B.B. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 45 (1975) 321-334
14. Anafi M., et al. Selective interactions of transforming and normal abl proteins with ATP, tyrosine-copolymer substrates, and tyrphostins. J. Biol. Chem. 267 (1992) 4518-4523
15. Anafi M., et al. Tyrphostin-induced inhibition of p210BCR-ABL tyrosine kinase activity induces K562 to differentiate. Blood 82 (1993) 3524-3529
16. Buchdunger E., et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 56 (1996) 100-104
17. Deininger M., et al. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105 (2005) 2640-2653
18. Deininger M.W., et al. BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia. Cancer Res. 60 (2000) 2049-2055
19. Drexler H.G., et al. Leukemia cell lines: in vitro models for the study of Philadelphia chromosome-positive leukemia. Leuk. Res. 23 (1999) 207-215
20. Greaves M.F., et al. "Pre-B" phenotypes in blast crisis of Ph1 positive CML: evidence for a pluripotential stem cell "target". Leuk. Res. 3 (1979) 181-191
21. Minowada J., et al. A non-T, non-B human leukemia cell line (NALM-1): establishment of the cell line and presence of leukemia-associated antigens. J. Natl. Cancer Inst. 59 (1977) 83-87
22. Deininger M.W., et al. The molecular biology of chronic myeloid leukemia. Blood 96 (2000) 3343-3356
23. Van Etten R.A. Studying the pathogenesis of BCR-ABL+ leukemia in mice. Oncogene 21 (2002) 8643-8651
24. McLaughlin J., et al. In vitro transformation of immature hematopoietic cells by the P210 BCR-ABL oncogene product of the Philadelphia chromosome. Proc. Natl. Acad. Sci. U S A 84 (1987) 6558-6562
25. Tordaro G.J., and Green H. An assay for cellular transformation by SV40. Virology 23 (1964) 117-119
26. Daley G.Q., et al. The CML-specific P210 bcr/abl protein, unlike v-abl, does not transform NIH/3T3 fibroblasts. Science 237 (1987) 532-535
27. Lugo T.G., and Witte O.N. The BCR-ABL oncogene transforms Rat-1 cells and cooperates with v-myc. Mol. Cell. Biol. 9 (1989) 1263-1270
28. Renshaw M.W., et al. Oncogenic v-Abl tyrosine kinase can inhibit or stimulate growth, depending on the cell context. Embo. J. 11 (1992) 3941-3951
29. Lugo T.G., et al. Tyrosine kinase activity and transformation potency of BCR-ABL oncogene products. Science 247 (1990) 1079-1082
30. Gaston I., et al. Abl kinase but not PI3-kinase links to the cytoskeletal defects in BCR-ABL transformed cells. Exp. Hematol. 28 (2000) 351
31. Gross A.W., and Ren R. BCR-ABL has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells in vivo. Oncogene 19 (2000) 6286-6296
32. Senechal K., et al. The CRKL adaptor protein transforms fibroblasts and functions in transformation by the BCR-ABL oncogene. J. Biol. Chem. 271 (1996) 23255-23261
33. Heaney C., et al. Direct binding of CRKL to BCR-ABL is not required for BCR-ABL transformation. Blood 89 (1997) 297-306
34. Era T., and Witte O.N. Regulated expression of P210 BCR-ABL during embryonic stem cell differentiation stimulates multipotential progenitor expansion and myeloid cell fate. Proc. Natl. Acad. Sci. U S A 97 (2000) 1737-1742
35. Kelliher M.A., et al. ABL oncogenes directly stimulate two distinct target cells in bone marrow from 5-fluorouracil-treated mice. Oncogene 8 (1993) 1249-1256
36. McLaughlin J., et al. In vitro transformation of immature hematopoietic cells by the P210 bcr/abl oncogene product of the Philadelphia chromosome. Proc. Natl. Acad. Sci. U S A 84 (1987) 6558-6562
37. Ramaraj P., et al. Effect of mutational inactivation of tyrosine kinase activity on BCR-ABL-induced abnormalities in cell growth and adhesion in human hematopoietic progenitors. Cancer Res. 64 (2004) 5322-5331
38. Zhao R.C., et al. A model of human p210(bcr/ABL)-mediated chronic myelogenous leukemia by transduction of primary normal human CD34(+) cells with a BCR-ABL- containing retroviral vector. Blood 97 (2001) 2406-2412
39. Heisterkamp N., et al. Human BCR-ABL gene has a lethal effect on embryogenesis. Transgenic Res. 1 (1991) 45-53
40. Kabarowski J.H., and Witte O.N. Consequences of BCR-ABL expression within the hematopoietic stem cell in chronic myeloid leukemia. Stem Cells 18 (2000) 399-408
41. Daley G.Q., et al. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247 (1990) 824-830
42. Zhang X., and Ren R. BCR-ABL efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia. Blood 92 (1998) 3829-3840
43. Pear W.S., et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 92 (1998) 3780-3792
44. Li S., et al. The P190, P210, and P230 Forms of the BCR-ABL Oncogene Induce a Similar Chronic Myeloid Leukemia-like Syndrome in Mice but Have Different Lymphoid Leukemogenic Activity. J. Exp. Med. 189 (1999) 1399-1412
45. Koschmieder S., et al. Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis. Blood 105 (2005) 324-334
46. Van Etten R.A. Retroviral Transduction Models of Ph+ Leukemia: Advantages and Limitations for Modeling Human Hematological Malignancies in Mice. Blood Cells Mol. Dis. 27 (2001) 201-205
47. Hawley R.G., et al. Versatile retroviral vectors for potential use in gene therapy. Gene Ther. 1 (1994) 136-138
48. Wong S., and Witte O.N. Modeling Philadelphia chromosome positive leukemias. Oncogene 20 (2001) 5644-5659
49. Wolff N.C., and Ilaria Jr. R.L. Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571. Blood 98 (2001) 2808-2816
50. Hu Y., et al. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat. Genet. 36 (2004) 453-461
51. Holyoake T.L., et al. Elucidating critical mechanisms of deregulated stem cell turnover in the chronic phase of chronic myeloid leukemia. Leukemia 16 (2002) 549-558
52. Lichtman M. Chronic myelogenous leukemia and related disorders. In: Beutler E., et al. (Ed). Williams Helatology (1995), McGraw-Hill 298-324
53. Petzer A.L., and Gunsilius E. Hematopoietic stem cells in chronic myeloid leukemia. Arch. Med. Res. 34 (2003) 496-506
54. Huntly B.J., et al. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell 6 (2004) 587-596